Theranostic CEST-enhanced thermoresponsive hydrogel drug delivery system for postsurgical treatment of glioblastoma

Key Points

• Theranostic CEST-enhanced delivery systems can improve postsurgical outcomes in glioblastoma treatments, offering targeted results.
• Key metrics suggest enhanced drug delivery efficiency, potentially improving therapy effectiveness and patient outcomes.
• This study utilizes a thermoresponsive hydrogel that releases medication more effectively in response to temperature changes after surgery.
• Highlighting the approach may enable wider application in clinical practice, although results require further evaluation in diverse settings.